The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.
The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.
The funding will help the consortium continue creating and updating PGx guidelines, adding drug-gene pairings, and creating electronic tables that can be integrated within EHRs.
The firm recently announced a $3.15 million grant from the NIH, and it supported work that resulted in the first-ever digital primary diagnosis of a suspected cancer case.
The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.
